Anaphylm Launch Stumbles Out of the Gate; Cash Burn Accelerates Amid Stiff Competition

What happened

Aquestive reported Q2 2026 results with Anaphylm revenue near the low end of internal forecasts, as payer discounting and neffy competition limited early script growth. Management highlighted initial formulary wins but conceded that net pricing is materially below launch assumptions due to aggressive rebating by rivals. With SG&A running at elevated levels to support the launch, the company's cash position fell to $98M from $129.1M at end of Q3 2025, raising doubts about its ability to refinance the 13.5% notes without dilution. The call also hinted at potential need for additional capital, either through the ATM or restructuring, if Anaphylm uptake does not accelerate in the second half. Despite optimistic rhetoric about patient demand, the financial trajectory mirrors the bear case outlined in prior analysis, with equity value increasingly subordinated to royalty and debt holders.

Implication

Investors should brace for continued volatility as the company likely needs to raise capital before achieving positive cash flow, which will dilute existing shareholders. The crowded 'needle-free epinephrine' trade is unwinding, and with neffy entrenched and payers demanding discounts, Anaphylm's path to meaningful share is narrowing. The 13.5% notes and layered royalties structurally cap equity upside even in a recovery scenario, making the stock a poor risk-adjusted hold at current levels. If management fails to disclose concrete payer wins and script acceleration by Q3, the stock could test the bear-case value of $3.50. A disciplined approach would be to trim positions above $8.50 as previously advised, and only consider re-entry near $4.50 if launch metrics improve or refinancing is secured on reasonable terms.

Thesis delta

The original thesis highlighted Anaphylm approval and launch as a binary catalyst with unfavorable skew; Q2 2026 results confirm approval occurred but launch is tracking below base-case assumptions. The competitive and funding risks have materialized, shifting the probability distribution toward the bear scenario and reinforcing the 'potential sell' rating.